Pain

FDA Approves Two New Strengths of Apadaz for Pain Management

By January 07, 2019

Apadaz was initially approved in February 2018 as 6.12mg/325mg immediate-release tablets for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

ZTlido Approved to Treat Pain Associated With Postherpetic Neuralgia

By February 28, 2018

ZTlido is comprised of a non-aqueous adhesive material containing 1.8% lidocaine.

FDA Approves Treatment for Two Neuropathic Pain Conditions

By October 12, 2017

The efficacy of Lyrica CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.